Rapid Micro Biosystems, a Lowell, MA-based provider of automated, growth-based, rapid microbial detection technology for the healthcare product manufacturing sector, secured $60m in equity financing.
The round was led by new investors Bain Capital Life Sciences and Xeraya Capital with participation from new investor Asahi Kasei Medical, along with continued participation from Longitude Capital, Quaker Partners, TVM Capital, and Richard K. Mellon and Sons.
The company intends to use the funds to accelerate global commercial expansion, operational capability and product innovation of its rapid microbial detection technology.
Led by Robert Spignesi, Chief Executive Officer, Rapid Micro Biosystems creates innovative products for fast and accurate detection of microbial contamination in the manufacture of pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company’s Growth Direct™ – is a growth-based system to automate traditional microbial testing – which detects contamination and improves their quality control (QC) process.